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Identification of Lethal Inhibitors and Inhibitor Combinations
for Mono-Driver versus Multi-Driver Triple-Negative Breast
Cancer Cells
Geng Chia Ku, Abygail G. Chapdelaine, Marina K. Ayrapetov and Gongqin Sun *
Department of Cell and Molecular Biology, University of Rhode Island, 120 Flagg Rd, Kingston, RI 02881, USA
* Correspondence: gsun@uri.edu; Tel.: +1-401-874-5937

Simple Summary: Triple-negative breast cancers lack estrogen and progesterone receptors and
HER2. They lack effective targeted therapies and tend to be more aggressive, with the worst five-year
overall survival and a higher rate of recurrence. This study investigates the oncogenic signaling
mechanisms of two model cell lines, DU-4475 and MDA-MB-231. The former is a mono-driver cancer
cell line relying on a BRAF V600E mutation and the latter is a multi-driver cancer dependent on a
KRAS-mutation-activated MAP kinase pathway and Src kinase. The results of this study reveal that
while the mono-driver cancer cells can be effectively killed by one drug blocking their predominant
driver, multi-driver cancer cells can only be killed by drug combinations blocking all drivers. The
drug combination in MDA-MB-231 achieves strong synergy and potent synthetic lethality. This study
suggests pharmacological synthetic lethality as a foundation for combination targeted therapy for
multi-driver cancers.
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Abstract: There are no signaling-based targeted therapies for triple-negative breast cancer. The development of targeted cancer therapy relies on identifying oncogenic signaling drivers, understanding
their contributions to oncogenesis and developing inhibitors to block such drivers. In this study, we
determine that DU-4475 is a mono-driver cancer cell line relying on BRAF and the mitogen-activated
protein kinase pathway for viability and proliferation. It is fully and lethally inhibited by BRAF or
Mek inhibitors at low nM concentrations, but it is resistant to inhibitors targeting other signaling
pathways. The inhibitory lethality caused by blocking Mek or BRAF is through apoptosis. In contrast,
MDA-MB-231 is a multi-driver triple-negative breast cancer cell line dependent on both Src and the
KRAS-activated mitogen-activated kinase pathway for proliferation and viability. Blocking each
pathway alone only partially inhibits cell proliferation without killing them, but the combination of
dasatinib, an Src inhibitor, and trametinib, a Mek inhibitor, achieves synthetic lethality. The combination is highly potent, with an IC50 of 8.2 nM each, and strikingly synergistic, with a combination index
of less than 0.003 for 70% inhibition. The synthetic lethality of the drug combination is achieved by
apoptosis. These results reveal a crucial difference between mono-driver and multi-driver cancer cells
and suggest that pharmacological synthetic lethality may provide a basis for effectively inhibiting
multi-driver cancers.
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1. Introduction
Breast cancer is the most common cancer in women and metastatic breast cancer is the
second-leading cause of cancer-related deaths in American women [1,2]. Triple-negative
breast cancer (TNBC) lacks an estrogen receptor (ER), progesterone receptor (PR), and
HER2 receptor. It accounts for ~15% of all breast cancers [3–5] and tends to be more
aggressive [6–8], with higher mean tumor size, tumor grade, the worst five-year overall
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survival, and a higher rate of recurrence [9–11]. It is more common in premenopausal and
African-American women [12–15].
A major reason for the poor outcomes for TNBC patients is the lack of effective targeted
therapies. Hormonal therapy, targeting ER [16,17], and small-molecule and antibody
therapies, targeting ErbB2 [11,18,19], have significantly improved treatments for ER+ and
HER2+ breast cancer patients. TNBC lacks these receptors and is heterogeneous in its
oncogenic mechanisms without predominant targets. Consequently, advanced TNBC
still relies on chemotherapies with anthracyclines, alkylating agents, and taxanes [20–22].
Metastatic TNBC has a 5-year survival rate of only 12% [23,24]. The lack of targeted therapy
for TNBC also epitomizes a general problem for targeted cancer therapy. In 2018, only
8.33% of all US cancer patients were genomically eligible for targeted therapies and only
4.9% benefited from such treatments [25]. Establishing predictive relationships between
biomarkers and effective treatments is urgently needed for better treatment of TNBC and
many other cancer types.
Among the eight cancer hallmarks [26,27], at least six are fully or partially supported
by oncogenic signaling: sustaining proliferative signaling, evading growth suppressors,
resisting cell death, inducing angiogenesis, activating invasion and metastasis, and reprogramming energy metabolism. Thus, blocking cancer signaling drivers is expected to be a
key component of effective targeted cancer therapies for TNBC [28–33]. TNBC frequently
displays an activated phosphatidylinositol 3-phosphate (PI3K) pathway due to PIK3CA
mutation (9%), PIK3CA amplification (49%) [3], PTEN mutation/loss (35%), and INPP4B
loss (30%). Many components of the mitogen-activated protein kinase (MAPK) pathways
are also amplified in TNBC, including KRAS (32%) and BRAF (30%) [3]. Some receptor
protein tyrosine kinases (rPTK), including EGFR, FGFR1, FGFR2, IGF-1R, KIT, MET, and
PDGFRA, are also amplified in TNBC [3]. Targeting the PI3K pathway (PI3K [34–37]
and AKT [38–40]), MAPK pathway [41–45], or PTKs (EGFR [46], FGFR [47–49], and Src
kinase [50–52]) has not been effective in treating TNBC in clinical trials.
While the underlying reasons for the lack of success in these clinical trials may be
complex, one plausible explanation is that most TNBC tumors are supported by multiple
oncogenic drivers, making targeted therapy against any one driver not effective. This
possibility can be fully explored by determining the oncogenic mechanisms in TNBC
tumors and model cell lines, while this obstacle can be overcome by developing effective
drug combinations against multi-driver cancers. This study demonstrates that TNBC cell
line DU-4475 is a mono-driver TNBC model predominantly driven by a BRAF V600E
mutation. We then compare the pharmacological properties of DU-4475 to those of MDAMB-231, a multi-driver TNBC cell line. The results reveal striking differences between
mono-driver and multi-driver cancer cells in their responses to protein kinase inhibitors and
suggest pharmacological synthetic lethality may provide a mechanistic basis for treating
multi-driver cancers.
2. Materials and Methods
2.1. Cell Lines, Media, and Drugs
The human TNBC cell lines, DU-4475 and MDA-MB-231 were purchased from ATCC
(Manassas, VA, USA). ATCC authenticated them by short tandem repeat profiling, cell
morphology monitoring, karyotyping, and cytochrome C oxidase I testing. The cells were
grown in RPMI-1640 and DMEM media, respectively, with 10% FBS and 1% penicillinstreptomycin (Thermo Fisher Scientific, Pittsburgh, PA, USA). They were cultured at
37 ◦ C in humid atmosphere containing 5% CO2 . Kinase inhibitors were purchased from
Selleckchem (Munich, Germany), LC Laboratories (Woburn, MA, USA), MedChemExpress
(Monmouth Junction, NJ, USA), or AdooQ Bioscience (Irvine, CA, USA).
2.2. Cell Culture and Viability Assays
Cell culture and viability assays were performed as described previously [53]. The
effect of a drug on cell viability was determined in 96-well plates using Biolog Redox
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Dye MA or MTT dye assay (Thermo Fisher Scientific) per the manufacturer’s instructions.
DU-4475 cells were cultured in suspension and plated at 10,000 cells per well in a 100 µL
medium containing the indicated drug and 1% DMSO. The cells were treated with indicated
drugs for 48 h at 37 ◦ C with 5% CO2- before the cell viability was determined using the
Biolog Redox Dye MA by calculating the differences in absorbance at 590 and 750 nm.
MDA-MB-231 cells are adherent cells and were seeded at 12,000 cells per well in 120 µL and
allowed to attach overnight. A culture medium containing the drug and 5% DMSO (30 µL)
was added to each well and the cells were cultured for 48 h before the cell viability was
determined by the MTT assay. The formazon product was determined by absorbance at
490 and 750 nm using a Biotek Microplate Reader. In the MTT assay, the A490 –A750 values
were taken as indicators of cell viability. All cell growth and drug inhibition experiments
were performed at least twice in triplicate.
2.3. Curve Fitting by the Hill Equation and the Biphasic Equation
Dose–response data were fitted to the Hill equation and the biphasic equation in
Microsoft Excel using the Solver add-in program. The Hill equation used was I = Imax ×
Dn /(IC50 *n + Dn ), where Imax is the maximal inhibition by a drug, IC50 * is the IC50 for
inhibiting the portion of cell viability that is sensitive to the drug, and is the Hill coefficient
or slope. The biphasic equation used was I = F1 × [D]/([D] + Kd1 ) + F2 × [D]/([D] + Kd2 ),
where the inhibition of cell viability (I) as a function of variable drug concentration is
determined by three constants: F1 , Kd1 , and Kd2 . The F2 was not an independent variable
but instead calculated as 100%-F1 . In Hill equation fitting, the root mean square error
(RMSE) was minimized using the Imax , IC50 * and n as variables. In biphasic curve fitting,
the RMSE was minimized using the F1 , Kd1 , and Kd2 as variables.
2.4. Drug Synergy Analysis and Combination Index Calculation
Drug synergy was evaluated by the combination index (CI) and the dose reduction
index (DRI), as described previously [53,54]. Cell viability was determined after incubation
in the presence of each drug alone or both drugs (1:1 ratio) at 16 concentrations ranging
from 0.6 nM to 20 µM. The CI was calculated according to Chou [55], using the Chou and
Talalay Method [55] with the following equation: CI = ICx-AB /ICx-A + ICx-AB /ICx-B , where
ICx-A , ICx-B , and ICx-AB are the concentrations of drug A, drug B, and drug AB combination,
causing X% inhibition of cell viability, respectively. DRI was calculated as 1/CI.
2.5. Time Course Experiments
To determine the time-dependent effects of drug treatments on cell viability of DU-4475
and MDA-MB-231, cells were treated with drugs at indicated concentrations as described in
Section 2.2 and the cell viability was determined 1 h, 24 h, 48 h, and 72 h after the treatments
were initiated.
2.6. Cell Treatments and Western Blots
To determine the effects of a protein kinase inhibitor or a combination of inhibitors on
the signaling proteins, cells were seeded at 70% confluency and treated with drugs at indicated concentrations for 1 h under normal cell culture conditions. After the treatment, the
cells were placed on ice, washed 1× with chilled PBS, and lysed in RIPA buffer containing
a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and protein phosphatase
inhibitors (PhosSTOP, Sigma-Aldrich) for 30 min at 4 ◦ C. Lysates were cleared at 21,000× g
for 10 min at 4 ◦ C. Protein concentrations of the supernatants were then quantified using a
BioRad Bradford Protein Assay. Then, 12–40 µg of protein was separated using a gradient
(4–20%) SDS-PAGE gel and transferred onto a nitrocellulose membrane. The membranes
were then blocked in 5% non-fat milk in TBST (Tris-buffered Saline with Tween 20) for 1 h
before probing with the indicated primary antibody overnight. Membranes were imaged
using LI-COR Odyssey CxL Imager and analyzed using Image Studio software (LI-COR
Biosciences, Lincoln, NE, USA). All antibodies were purchased from Cell Signaling Tech-
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nology (Danvers, MA, USA). The density of each protein band in the Western blots was
measured using ImageJ 1.53K software [56].
2.7. DU-4475 Apoptosis and Necrosis Assay
DU-4475 cell apoptosis and necrosis in response to trametinib treatment are monitored
using the RealTime-Glo Anexin V Apoptosis and Necrosis assay (Promega, Madison, WI,
USA) [57]. DU-4475 cells were seeded at 10,000 cells per well in 100 µL medium with or
without trametinib in 96-well white plates with clear bottoms. Apoptosis and necrosis
assay reagents (100 µL) were added and the cells were incubated at 37 ◦ C and 5% CO2 .
Each well contained 1% DMSO, 20 nM trametinib (treatment) or no drug (control). The
plate was shaken for 30 s at 500–700 rpm before the luminescence and fluorescence (485
nmEx /528 nmEm ) in each well were recorded every 6 h, using a Biotek Synergy HTX multimode reader (Agilent Technologies, Santa Clara, CA, USA). The assay was performed in
quadruplicates and the average ∆Lum (luminescence of treatment—control) and ∆Fluo
(fluorescence of treatment—control) are reported.
3. Results
3.1. DU-4475 Cell Line Is Exceptionally Sensitive to BRAF and Mek Kinase Inhibitors
We previously reported that TNBC cell lines, MDA-MB-231 and MDA-MB-468, are
each dependent on two signaling pathways and can be effectively inhibited by inhibitor
combinations blocking both pathways [53]. To evaluate if most or all TNBC cell lines
are multi-driver cancer cells that cannot be blocked by any individual signaling kinase
inhibitors, we examined the drug response data of all TNBC cell lines in the Genomics of
Drug Sensitivity in Cancer database [58]. Table 1 lists 17 TNBC cell lines and the IC50 for
each cell line’s most potent protein kinase inhibitors for targeted therapy. Most of the TNBC
cell lines do not respond potently to any protein kinase inhibitors, displaying high nM to
low µM IC50 s. The only exception is DU-4475, which is potently inhibited by the BRAF
inhibitor dabrafenib (IC50 = 6.3 nM) and the Mek inhibitor trametinib (IC50 = 0.5 nM).
These data suggest that most TNBC cell lines do not depend on any single kinase for
viability, while DU-4475 is dependent on BRAF and Mek for viability. This suggestion is
consistent with DU-4475 being a mono-driver cancer cell line and the others reported are
multi-driver cancer cell lines.
Table 1. TNBC cell lines and their most potent signaling protein kinase inhibitors in the Genomics of
Drug Sensitivity in Cancer (GDSC1) database.
Cell Line

Most Potent
PKI

Target

IC50 (nM)

Z-Score

BT-20
BT-549
DU-4475
DU-4475
HCC1143
HCC1187
HCC1395
HCC1599
HCC1806
HCC1937
HCC38
HCC70
HCC70
Hs-578-T
MDA-MB-157
MDA-MB-231
MDA-MB-436
MDA-MB-453
MDA-MB-468

AKT inhibitor III
GW441756
Dabrafenib
Trametinib
Jak3_7406
GW441756
Panopanib
Jak1_3715
GSK1904529A
WZ3105
AKT inhibitor III
AKT inhibitor III
MK-2206
AT7868
Motesanib
Alectinib
GW441756
FGFR_0939
Amuvatinib

Akt
NTRK1
BRAF
Mek
Jak3
NTRK1
CSF1R, KIT, PDGFR
Jak 1
IGF1R, IR
Src, Rock2, NTRK2, FLT3
Akt 1, 2, 3
Akt 1, 2, 3
Akt 1, 2
Akt
VEGFR, RET, KIT, PDGFR
Alk
NTRK1
FGFR4
Kit, PDGFRA, FLT3

3505
3036
6.3
0.5
6312
89.7
2432
2185
3466
273
2085
775
1245
1160
6243
4639
5057
643
1267

−1
−1.3
−3.5
−2.1
−1.3
−4.7
−1.7
−3.9
−1.4
−0.8
−1.6
−2.6
−2.2
−2
−0.8
−2
−0.8
−2.6
−2.2
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In this study, we aimed to determine whether DU-4475 was truly a mono-driver
cancer cell line. DU4475 was derived from a cutaneous metastatic nodule from a patient
with advanced TNBC [59,60]. Even though DU-4475 has been widely used as a model
cell line to study the oncogenesis of TNBC, the oncogenic mechanism of this cell line is
not established. According to the COSMIC database [61], DU-4475 contains two notable
mutations: a truncation mutation at E1577 in the APC gene and a point mutation (V600E)
in BRAF. APC is a tumor-suppressor gene and its deletion and point mutations correlate to
the development of numerous types of cancers, especially colorectal cancers. BRAF with a
V600E mutation is a well-established oncogene in melanoma and colorectal cancer, but it is
rarely found in breast cancer. We investigated what signaling drivers were responsible for
the proliferation and viability of this cell line.
3.2. Probing Oncogenic Protein Kinase Drivers in DU-4475 Cell Line Viability
To determine what signaling pathways are essential for the viability of DU-4475
cells, we screened it against a panel of 20 protein kinase inhibitors (PKI) (Table 2). These
inhibitors included 10 PKIs against various receptor protein tyrosine kinases that have been
associated with some cancer types. Other intended targets included protein kinases in the
MAPK pathway, PI3K pathway, and Src kinases. Many of these kinases are suggested to be
involved in TNBC development.
Table 2. Protein kinase inhibitors used to probe the oncogenic signaling mechanism of DU-4475.
Inhibitor

Main Target Kinase

Signaling Pathway

Alectinib
BMS-754807
Cabozantinib
Crizotinib
Erdafitinib
Erlotinib
Lapatinib
Nintadenib
Regorafenib
Sunitinib
MK-2206
GSK690693
Vemurafenib
Dabrafenib
Trametinib
Binimetinib
Bosutinib
Dasatinib
Saracatinib
Nilotinib

Alk, Ret
Insulin receptor, IGF-1R
Tet, VEGFR
Alk, Ros1, Met
FGFR
EGFR
EGFR
VEGFR, PDGFR, FGFR
VEGFR
PDGFR, VEGFR
Akt
Akt
BRAF
BRAF
Mek
Mek
Src, Abl
Src, Abl
Src, Abl
Abl

Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
Receptor PTKs
PI 3-Kinase pathway
PI 3-kinase pathway
MAP kinase pathway
MAP kinase pathway
MAP kinase pathway
MAP kinase pathway
Cytoplasmic PTKs
Cytoplasmic PTKs
Cytoplasmic PTKs
Cytoplasmic PTKs

Most of the inhibitors are approved as treatments for appropriate cancers. Figure 1
shows the responses of DU-4475 to these drugs at four concentrations from 10 nM to 10 µM.
DU-4475 cells did not strongly respond to Akt inhibitors (Figure 1a), Src or Abl inhibitors
(Figure 1b), nor ten inhibitors against various receptor PTKs (Figure 1c). However, they
were potently inhibited by a BRAF inhibitor, dabrafenib, and two Mek inhibitors, trametinib
and binimetinib (Figure 1d). The most potent inhibitor was trametinib, which appeared to
fully inhibit DU-4475 viability at 10 nM. These results are consistent with the GDSC1 data.
To better characterize the response of DU-4475 to these drugs, cell responses to the
BRAF and Mek inhibitors at 16 concentrations were determined (Figure 2a). The dose–
response data to these four drugs were fitted to the Hill equation and the inhibitory
parameters are shown in Table 3. The data confirmed that DU-4475 cells are most sensitive
to trametinib, followed by dabrafenib and binimetinib. The IC50 of 0.28 nM for trametinib
is more potent in DU-4475 than previously reported inhibition of any other cancer cell
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line [62]. It is also notable that vemurafenib showed only mild inhibition, with an IC50 of
507 nM, while dabrafenib was much more potent, with an IC50 of 2.4 nM. All four drugs
inhibited the cell viability to 95% or more (Imax ) and the inhibition displayed mild positive
cooperativity in inhibiting cell viability, with the n values above 1. These characteristics
indicate that each drug can shut down DU-4475 viability by binding to a single high-affinity
target, BRAF or Mek. This result suggests that DU-4475 cells are solely dependent
on
7 of 22
BRAF signaling for viability. Considering that DU-4475 contains an oncogenic BRAF V600E
mutation, these data suggest that DU-4475 is a mono-driver cancer cell line.
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The inhibitory parameters were calculated by fitting 16 concentration dose–response data to the
Hill equation as described in Materials and Methods. Average and standard errors were calculated7 of 20
from six sets of data from two triplicate assays.
1
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To confirm that these drugs are blocking the intended targets, we determined the
To confirm that these drugs are blocking the intended targets, we determined the
effects of drug treatments on the phosphorylation states of key protein kinases in the MAP
effects of drug treatments on the phosphorylation states of key protein kinases in the
kinase pathway (Figure 2b). BRAF was phosphorylated on Ser445 in untreated cells and
MAP kinase pathway (Figure 2b). BRAF was phosphorylated on Ser445 in untreated cells
the phosphorylation level was not affected by any of the inhibitors. Trametinib and
and the phosphorylation level was not affected by any of the inhibitors. Trametinib and
dabrafenib nearly fully blocked the phosphorylation of Mek (Ser217 and Ser221) and Erk
dabrafenib nearly fully blocked the phosphorylation of Mek (Ser217 and Ser221) and Erk
(Thr202/Tyr204) at 10 nM and 100 nM, respectively, while vemurafenib only inhibited
(Thr202/Tyr204) at 10 nM and 100 nM, respectively, while vemurafenib only inhibited their
phosphorylation at 1000 nM. These observations are consistent with the potency of each
drug, inhibiting cell viability.
It is notable that trametinib not only inhibited Erk phosphorylation by Mek, but also
inhibited Mek phosphorylation by BRAF. This pattern of inhibition by trametinib is consistent with its reported mechanism of action [63–65]. Even though trametinib is generally
referred to as an Mek inhibitor, it more potently inhibits Mek phosphorylation by BRAF
than it inhibits Mek phosphorylation of Erk. This is achieved by interfering with BRAF’s
ability to recognize Mek, even though it is not a general BRAF inhibitor in phosphorylating
other BRAF substrates [63]. Thus, trametinib should be more accurately referred to as an
inhibitor of Mek activation by BRAF rather than an inhibitor of Mek activity.
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The data can also be viewed as DU-4475 dose–response curves for the 1 h and 48 h
treatments in Figure 3b. The presence of trametinib up to 0.8 nM allowed some increase
in DU-4475 viability in 48 h, indicating continued proliferation, albeit at reduced rates
compared to the control. Treatment with trametinib at 4 nM and 20 nM for 48 h resulted
in cell viability levels significantly below the original 1 h cell viability, indicating that the
treatments induced death. The crossover of the 48 h dose–response curve from above
to below the 1 h curve reveals the threshold of the drug concentration between growth
inhibition to cell killing.
Blocking BRAF function with dabrafenib resulted in similar cell responses by DU4475 (Figure 3c), killing cells in a concentration-dependent manner. The trametinib and
dabrafenib results together indicate that partial blocking of BRAF or Mek resulted in an in-
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hibition of DU-4475 proliferation, while complete inhibition of BRAF or Mek signaling fully
blocked DU-4475 proliferation and caused cell killing. These results strongly suggest that
DU-4475 is a mono-driver cancer cell line predominantly supported by a single oncogenic
signaling driver, BRAF V600E.
We determined if the DU-4475 killing by trametinib was via apoptosis. DU-4475 cells
treated with trametinib for 48 h were collected and the cleavage of apoptotic caspases and
poly (ADP-ribose) polymerase (PARP) was analyzed. The cleavage of caspases activates
them and initiates apoptosis. The cleavage of PARP inactivates it and suppresses DNA
repair, which is also associated with apoptosis. Caspases 3, 7, and 9 were cleaved to
expected sizes in response to trametinib treatments (Figure 3d). PARP was cleaved into an
89 kD fragment, which is also an indicator of apoptosis. These results suggest that blockage
of the predominant driver pathway by trametinib is sufficient to inhibit cell proliferation
and induce apoptosis in DU-4475 cells.
We used the Annexin V apoptosis and necrosis assay to confirm that trametinib caused
cell death in DU-4475 through apoptosis. The RealTime-Glo™ Annexin V Apoptosis and
Necrosis Assay (Promega, Madison, WI, USA) measures the real-time translocation of phosphatidylserine on the outer leaflet of cell membranes during early apoptosis [57]. The assay
also measures the loss of membrane integrity using a DNA-binding dye, which enters the
cell and generates a fluorescent signal. Figure 4a displays the increase in the luminescence
and fluorescence in DU-4475 cells due to trametinib treatment. The differential in luminescence signal between treated and control cells peaked at 11 h of treatment, an indication of
early apoptosis. The subsequent loss of the luminescence signal is an indication of the loss
of membrane integrity. This indicated that early apoptosis started at ~10 h treatment. The
fluorescence signal increased gradually following early apoptosis, corresponding
to the
Cancers 2022, 14, x FOR PEER REVIEW
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loss of membrane integrity due to necrosis. These results are consistent with the Western
blotting results, indicating that trametinib caused apoptosis and secondary necrosis.
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Assay as described in Materials and Methods. ∆Lum is the difference in luminescence of trametinibtreated cells—that of control cells. The increase in luminescence is an indication of phosphatidyl
Serine translocating to the outer leaflet of the cell membrane. ∆Fluo is the difference in fluorescence
of a DNA-binding dye in trametinib-treated cells—those of control cells. The increase in fluorescence
is an indication of cell membrane becoming permeable to the DNA binding dye. (b) Morphology of
control and trametinib-treated DU-4475 cells.

The morphology of the DU-4475 cells upon trametinib treatment is consistent with
this result (Figure 4b). The cells in the control at 24 h or 48 h grew in suspension, displayed
some loose association, and maintained a clean medium. The 20 nM trametinib-treated
DU-4475 cells at 24 h displayed various degrees of apoptotic blebbing and necrosis. At 48 h,
virtually all cells progressed to necrosis, with cell fragments and debris remaining. These
morphological changes confirmed the Western blotting results showing the activation of
caspases and degradation of PARP and the Annexin V assay results, showing apoptosis
and necrosis.
3.5. MDA-MB-231 Is a Multi-Driver TNBC Cell Line Dependent on Both the MAP Kinase
Pathway and Src Kinase for Proliferation
We next compared the inhibitory properties of DU-4475 and MDA-MB-231 based on
the following two considerations. First, the remarkable potency of trametinib in blocking
proliferation and inducing apoptosis in DU-4475 prompted us to examine if this drug
can be used to block the proliferation of other TNBC cells with activated MAP kinase
signaling. Among the available TNBC cell lines, DU-4475 is the only one with a BRAF
V600E mutation; however, MDA-MB-231 contains an oncogenic KRAS G13D mutation. It
has been reported that MDA-MB-231 is vulnerable to Mek inhibition by selumetinib [66,67].
Second, we previously determined that MDA-MB-231 is driven by both Src and the MAPK
pathway [53], making MDA-MB-231 a multi-driver cancer cell line. A comparison between
DU-4475 and MDA-MB-231 might offer insights into the multi-driver versus mono-driver
oncogenic mechanisms.
We compared the inhibition of MDA-MB-231 by different Mek inhibitors and dasatinib,
an Src inhibitor (Table 4). Consistent with our previous report on MDA-MB-231, individual
Mek inhibitors, trametinib, selumetinib, or binimetinib, are not potent inhibitors of MDAMB-231, reaching only a maximal inhibition of 43% for selumetinib and somewhat less for
the other two inhibitors. However, even with partial inhibition, trametinib displayed a
better potency (Kd = 13 nM) than the other Mek inhibitors (Kd of 563 nM and 199 nM for
selumetinib and binimetinib, respectively) at achieving the maximal inhibition. The lack of
full inhibition of MDA-MB-231 cell viability by these inhibitors is not due to restricted cell
permeability nor failure to bind to their intended targets. Each drug effectively inhibited
the phosphorylation and activation of Erk, trametinib at 10 nM and both binimetinib and
selumetinib at 100 nM (Figure 5). Consistent with trametinib being an inhibitor of Mek
activation by BRAF, trametinib also inhibited Mek phosphorylation, while binimetinib and
selumetinib did not. These results suggest that blocking Mek and Erk in the MAP kinase
pathway is not sufficient to block the viability of MDA-MB-231 cells. This suggestion is
consistent with MDA-MB-231 being a multi-driver cancer cell line.
Dasatinib inhibited MDA-MB-231 in a biphasic manner, with the first phase accounting for 55% of cell viability and a Kd1 of 27 nM. This pattern is similar to what has been
previously reported [53]. These analyses confirmed that the MAP kinase pathway and
Src are independent drivers in MDA-MB-231. Thus, we tested the effects of dasatinib
and trametinib combination on MDA-MB-231 viability. The combination of equal concentrations was an extremely potent inhibitor cocktail for this cell line, with an IC50 of
8.2 nM (Figure 6a and Table 4), about 10-fold more potent than dasatinib + selumetinib or
dasatinib + binimetinib combinations (Table 4). At the end of 48 h treatments, dasatinib
(100 nM) and trametinib (100 nM)-treated cells displayed similar morphology to control
cells. In contrast, the combination-treated cells were killed, with some cell debris remaining
(Figure 6b).
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Table 4. Inhibition 1 of MDA-MB-231 by individual and combination PKIs.

Inhibitor
Inhibitor
Dasatinib
Trametinib
Binimetinib
Selumetinib
Dasa + Tram
Dasa + Bini
Dasa + Selu

Hill Analysis
n
Imax (%)
66 ±Imax
8.5(%) 0.65 ± 0.03
F1 (%)73 ± 1.3
13 ±731.3
26 ± 3.1
± 1.3 0.97 ± 0.03
55 ± 0.8
± 3.1 0.92 ± 0.07
22 ± 1.9
199 26
± 5.8
19 ± 0.5
± 0.5 0.74 ± 0.11
16 ± 0.5
563 19
± 172
43 ± 4.7
43 ± 4.7
28 ± 3.8
8.2 ± 0.3 0.75 ± 0.03 98 ± 0.4
98 ± 0.4
ND
64 ±992.9
± 0.5 0.90 ± 0.03
ND 99 ± 0.5
78 94
± 11
0.71
±
0.04
± 0.3
ND 94 ± 0.3

Hill Analysis IC50 (nM)
IC50 (nM)
66 ± 8.5
13 ± 1.3
199 ± 5.8
563 ± 172
8.2 ± 0.3
64 ± 2.9
78 ± 11

Dasatinib
n
Trametinib
0.65 ± 0.03
0.97 ± 0.03
Binimetinib
0.92 ± 0.07
Selumetinib
0.74 ± 0.11
Dasa + Tram
0.75 ± 0.03
Dasa
0.90+±Bini
0.03
Dasa
0.71+±Selu
0.04

Biphasic Analysis
F2 (%) Kd2 (μM)
27 ± F3.3
45
± 0.8 Kd2
18(µM)
± 0.5
(%)
2
7.7 ±452.9
79
±
1.9
>100
± 0.8
18 ± 0.5
± 1.9
125 79
± 21
84 ± 0.5 >100
>100
± 0.5
>100
156 84
± 55
72 ± 3.9 97
± 13
72 ± 3.9
97 ± 13
ND
ND
ND
ND
ND
NDND ND
ND
ND
NDND ND
ND
ND

FBiphasic
1 (%)
KAnalysis
d1 (nM)
55(nM)
± 0.8
Kd1

1.9
2722±±3.3
7.7
16±±2.9
0.5
125
28±± 21
3.8
156 ± 55
ND
ND
ND
ND
ND
ND
1 These inhibitory parameters were obtained by analyzing dose response data at 16 concentrations
1 These inhibitory parameters were obtained by analyzing dose response data at 16 concentrations by the Hill
byequation
the Hilland
equation
and analysis
the biphasic
analysis
as described
in Materials and Methods.
the biphasic
as described
in Materials
and Methods.
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of MDA-MB-231 viability at 100 nM, while either drug alone did not reach that
inhibition at 20 µM. The synergy is strong at all inhibition levels and it becomes especially
striking at 60% or higher levels of inhibition. For example, the IC70 (drug concentration
for 70% inhibition) is 25 nM for the combination, 12.6 µM for dasatinib and above 20 µM
for trametinib. These numbers translate into a combination index (CI) below 0.0039 and a
dose-reduction index (DRI) above 257 [55,68] (Figure 6c). Thus, the drug combination is
>250-fold more potent than dasatinib and trametinib combined if there was no synergy. This
combination offers the most potent targeted drug combination for this cell line. The potency
is even more favorable than some targeted drugs for mono-driver cancers approved for
clinical applications.
To determine if the dasatinib/trametinib combination is specific for MDA-MB-231 cells,
we compared the inhibition of MDA-MB-231 to that of MDA-MB-468 (Figure 6d). MDA-MB468 has been shown to overexpress EGFR and lack PTEN and it is sensitive to inhibition
by the combination of lapatinib and GSK-690693. MDA-MB-468 cells are >1000-times
more resistant to the combination of dasatinib and trametinib, with an IC50 above 10 µM.
This result demonstrates that the sensitivity of MDA-MB-231 to the dasatinib/trametinib
combination is determined by the unique oncogenic driving mechanism in this cell.
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did not kill the cells up to 1 µM. Similarly, the 48 h dose–response curves for dasatinib were
MDA-MB-468 has been shown to overexpress EGFR and lack PTEN and it is sensitive to
above the 1 h treatment at all concentrations (Figure 7c), indicating that dasatinib inhibited
inhibition by the combination of lapatinib and GSK-690693. MDA-MB-468 cells are >1000cell growth but did not kill the cells up to 1 µM. In contrast, the dose–response curve for
the 48 h combination treatment was above the 1 h curve below 10 nM and crossed over to
below the 1 h curve at 100 and 1000 nM (Figure 7d). This cross-over pattern indicated that
the number of viable cells after 48 h treatment with the drug combination dropped below
that of the amount observed at 1 h, indicating that cells were killed in the combination
but not with trametinib or dasatinib alone. Western blotting (Figure 7e) demonstrated that

Induces Apoptosis in MDA-MB-231
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The strong synergy between dasatinib and trametinib prompted us to further investigate the mechanism of the drug combination. Figure 7a displays the growth curves of
MDA-MB-231 in the presence of 1 μM trametinib, dasatinib, and their combination. Dasatinib or trametinib alone at 1 μM resulted in a slower increase in cell viability up
to 72
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h, but neither decreased cell viability. The combination of dasatinib and trametinib at 1
μM resulted in a slight increase in cell viability up to 24 h and a dramatic decrease in cell
viability in 48 h and 72 h, indicating that the combination resulted in near-complete cell
the drug combination at 100 nM caused significant cleavage of caspases 3, 7, and PARP,
killing (Figure 7a).
indicating cell death is through apoptosis.
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The increase in apoptosis when both pathways are blocked also provides a mechanistic
explanation for the dramatic synergy observed earlier. When only one driver is blocked
by a drug, the cells are still able to survive or even grow with the support of the other
pathway. When both drivers are blocked, the cells lose all growth stimulation and initiate
apoptosis. This is in direct contrast with that of DU-4475, for which apoptosis is induced by
one drug. These results suggest that a drug blocking one driver can kill mono-driver cancer
cells, but a multi-driver cancer cell can be killed only by a drug combination blocking both
signaling pathways.
4. Discussion
Despite dramatic progress in targeted cancer therapies blocking oncogenic signaling,
only a relatively small number of cancers have benefitted from effective therapy and most, if
not all, effectively treated cancers are mono-driver cancers. Most cancers are dependent on
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multiple drivers, making them naturally resistant to treatments targeting any single driver.
Triple-negative breast cancers appear to be mostly multi-driver cancers. Understanding the
molecular basis of multi-driver versus mono-driver oncogenesis is a major challenge for
developing targeted therapies for TNBC.
4.1. DU-4475 as a Mono-Driver Cancer Cell Model
This study provides evidence that DU-4475 is a mono-driver cancer cell line. DU-4475
cells harbor a BRAF V600E mutation, but the functional significance of this mutation in
this cell line is not fully clear. While BRAF V600E is a predominant driver in some cells,
especially in melanoma, other cells with this mutation are not entirely dependent on it for
oncogenic proliferation. In DU-4475, blocking BRAF or Mek kinase alone is sufficient to
completely block cell viability and cause apoptosis (Figures 2–4). These results suggest
that BRAF V600E-activated MAP kinase signaling is essential for the survival of DU-4475
cells and blocking this pathway at either step is sufficient to kill DU-4475 cells. To our
knowledge, this is the only TNBC cell line that is dependent on a single oncogenic driver,
i.e., a mono-driver cancer cell line.
The inhibition of a mono-driver cancer cell line by the inhibitor for its driver displays
three characteristics when the dose–response data are fitted into the Hill equation: an
IC50 consistent with the target kinase inhibition, an Imax close to 100%, and a Hill slope, n,
around 1. When a cell response to a given PKI meets these criteria, the target kinase of the
drug can be considered the predominant driver and the cancer cell can be considered a
mono-driver cancer cell. DU-4475 cells meet these criteria as they are potently and fully
inhibited by BRAF or Mek inhibitors, demonstrating the cells’ dependence on BRAF V600E
for cell viability. The most noteworthy drug is trametinib, which inhibited DU-4475 cells
with an IC50 of 0.28 nM and reached 95% inhibition at about 1 nM. It can be expected that
cancer with a similar mechanism would be susceptible to targeted therapy with trametinib.
4.2. BRAF V600E as a Therapeutic Target in TNBC
A BRAF mutation is rare in breast cancer and TNBC, but several-BRAF V600E-driven
TNBC cases have been reported. Pircher et al. reported [69] that a 38-year-old female
TNBC patient with a BRAF V600E mutation developed multiple lung metastases. The
patient was treated with vemurafenib, which resulted in clear radiological improvements
within three months. At the time of the report (19 months after the therapy started),
the lung metastases remain radiologically stable and the patient remains in good clinical
condition. The second case of a TNBC patient with a BRAF V600E mutation was reported
by Wang et al. [70]. This 60-year-old patient was first treated with chemotherapy to
achieve a 7-month progression-free survival (PFS). The patient received vemurafenib and
albumin-bound paclitaxel as a second-line therapy, exhibiting regression of some metastatic
pulmonary lesions with concomitant progression of other lesions and achieved a 4.4-month
PFS. Genetic testing of the progressed pulmonary lesion revealed the presence of the BRAF
V600E mutation together with other newly acquired mutations in PDGFRB, NF2, GRM3,
MLH1, FOXA1, LRP1B, and amplification of androgen receptor. The patient ultimately
died of multiple organ failure and achieved 12 months of overall survival. The third
TNBC patient with a BRAF V600E mutation was a 57-year-old woman with metastatic
TNBC and chemotherapy-refractory massive pleural effusion [71]. She also had oncogenic
PIK3CA H1047R mutation, among others. After failure with anthracycline- and taxanebased chemotherapy and palliative radiotherapy, the patient was treated with a dabrafenib
and trametinib combination. The patient exhibited improved conditions with decreases in
swelling and pain, a decrease in pleural fusion, and a reduction in the size of the axillary
lymph nodes for several weeks. However, the patient developed another subcutaneous
tumor and died 12 weeks after initiating the dabrafenib/trametinib treatment. All three
case reports support BRAF V600E as a valid treatment target in TNBC. These case studies
also make it clear that the acquisition of additional oncogenic driver mutations would
make it ineffective to treat the patient with a BRAF inhibitor alone and finding effective
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drug combinations that block all oncogenic drivers would be necessary. The presence of the
H1047R mutation in PIK3CA, a well-established oncogenic driver [72], in the third patient,
suggests that the PI 3-kinase pathway is also activated in this patient, likely making it a
multi-driver cancer. A drug combination blocking both BARF and the PI 3-kinase pathway,
such as PI 3-kinase inhibitors or Akt inhibitors, may have been more effective than the
dabrafenib and trametinib combination.
4.3. Blocking Both Oncogenic Drivers in MDA-MB-231 Causes Synthetic Lethality
Most cancers are likely dependent on multiple oncogenic drivers. We previously
demonstrated that several colorectal cancers and TNBC cell lines are multi-driver cancer
cells, including MDA-MB-231. The identification of a mono-driver cancer cell model in
DU-4475 enabled us to compare the drug response patterns of a mono-driver versus a
multi-driver cancer cell model. While blocking the predominant driver in a mono-driver
cancer cell line is sufficient to fully inhibit cell proliferation and cause cell death, blocking a
driver in a multi-driver cancer model only causes partial inhibition to cancer viability and
does not kill the cancer cells. The MDA-MB-231 cells are dependent on the MAP kinase
pathway and Src signaling for survival and blocking either the MAP kinase pathway or Src
only partially inhibits cell viability and without causing cell death. Only the combination
of Src and Mek inhibitors completely inhibits cell proliferation and causes programmed cell
death. This crucial difference between mono-driver and multi-driver cancer cells provides
an explanation why single-agent targeted therapy only works well for mono-driver cancer
cells but not for multi-driver cancer cells and supports combination targeted therapy as a
viable strategy against multi-driver cancers.
The drug combination is also strikingly synergistic. Dasatinib displays a biphasic
inhibition with a potent phase 1 (F1 = 55% and Kd1 = 27 nM) and an F2 of 45% with Kd2
of 18 µM. With both phases combined, dasatinib is still not an effective inhibitor, reaching
70% inhibition at 12.5 µM. Trametinib alone is even less effective, only causing a maximal
inhibition of ~20%. However, the combination is much more potent, with an IC50 of 8.2 nM,
and achieved near-complete inhibition at about 100 nM. The strong synergy is also reflected
in the CI of <0.003 and DRI > 300. This striking synergy can be explained by the multi-driver
oncogenic mechanism. Because the cells are supported by two pathways, blocking either
Src or the MAP kinase pathway alone still leaves the cells viable and only blocking both
pathways causes cell death. The striking synergy supports the potential effectiveness of
combination targeted therapy for multi-driver cancers.
4.4. Single-Drug Lethality versus Synthetic Lethality
An ideal cancer drug should inhibit cancer cell growth and cause cancer cell lethality
with specificity. Our data demonstrate that for mono-driver cancer cells, such as DU-4475,
the specific lethality is achieved with a single drug at low nM concentrations. This is
presumably the underlying basis for the success of targeted therapies against mono-driver
cancers. Because multi-driver cancer cells can survive with the support of multiple drivers,
pharmacological lethality is not achievable with any one targeted drug blocking any driver
and is only achievable when a drug combination blocking all drivers is used. Combinational
inhibition of MDA-MD-231 can be considered a form of pharmacological synthetic lethality.
This pharmacological synthetic lethality is rooted in the multi-driver nature of MDAMB-231 cells, as they have acquired an overlapping dependence on the MAP kinase
pathway and Src kinases. The partial functional redundancy between these two pathways
likely makes MDA-MB-231 cells much more resilient and gives them a significant growth
advantage and adaptability. The advantage of this multi-driver overlapping mechanism to
the cancer cells is evident and likely applicable to other multi-driver cancer cells. Further
research is needed to establish this as a broadly utilized mechanism.
Traditionally, synthetic lethality is defined at the genetic level, where the loss-offunction mutations in two genes cause lethality [73,74], while the loss of either gene alone
is not lethal. This concept was further expanded to include the lethality caused by genetic
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mutation in one gene and chemical inhibition of another. For example, BRCA1 and BRCA2
mutations and PARP inhibitors are synthetically lethal, which has become the conceptual
basis for the new therapeutic paradigm of PARP inhibition for cancer patients carrying
BRCA1 and BRCA2 mutations [75]. The pharmacological synthetic lethality between
dasatinib and trametinib observed in MDA-MB-231 cells carries this concept a step further.
This concept could provide a molecular basis for combination targeted therapies in multidriver cancers.
5. Conclusions
Triple-negative breast cancer is notoriously heterogeneous, with different patients
using different genetic and biochemical mechanisms of oncogenesis. This heterogeneity is
clearly illustrated in the two cancer cell lines used in this study. Even though both DU-4475
and MDA-MB-231 have mutations in the MAP kinase pathway, BRAF V600E in DU-4475
and KRAS G13D in MDA-MB-231, these two cell lines have one critical difference. While
DU-4475 is a mono-driver cancer cell line, solely dependent on BRAF for survival and
proliferation, MDA-MB-231 relies on both the MAP kinase pathway and Src signaling.
Comparing these cell lines offers critical insights into mono-driver versus multi-driver
oncogenesis and strategies for blocking them.
The results demonstrated that DU-4475 cells, as mono-driver cancer cells, can be
blocked and killed by BRAF or Mek inhibitors. The MDA-MB-231 cells, in contrast, can
still survive when either the MAP kinase pathway or Src kinases are fully inhibited. The
cells can only be killed when both pathways are blocked. This pharmacological synthetic
lethality offers an underlying basis for killing multi-driver cancer cells by targeted drug
combinations. In both cases, cell killing was achieved through apoptosis. These results
explain why successful targeted therapies are against mono-driver cancers and offer a proof
of concept for a mechanism-based combination targeted therapy strategy for multi-driver
cancers. It is well observed that broadly targeting protein kinase inhibitors are generally
more toxic toward more cells than those with narrow inhibitory specificity. However, such
broadly targeted drugs tend to cause general toxicity. Identifying the oncogenic drivers and
drug combinations to specifically block the oncogenic drivers through combination therapy
is a plausible precision approach to achieve multi-target inhibition without causing general
toxicity. Further validation is needed to determine if this strategy is broadly applicable.
While most TNBC cancers are expected to be multi-driver cancers, the functional signaling
drivers have yet to be identified in most TNBC models. The elucidation of signaling drivers
in other TNBC cell models will further validate this strategy.
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